Agreement to carry out screening against a variety of targets and whole cell screens using established library of compounds
Asinex, a European provider of lead generation and optimisation services, announces a drug discovery collaboration with F2G, a drug discovery company specialising in developing new treatments for systemic fungal infection, to carry out screening against a variety of targets and whole cell screens using Asinex's compounds.
Asinex will provide F2G with selected compounds from within its library and allow F2G to screen and develop these compounds as anti-fungal drugs.
Screening will be conducted at F2G's laboratory in Manchester, UK.
As active compounds suitable for pre-clinical and clinical development are identified and selected, the intellectual property rights of these compounds will belong to F2G.
Alex Lemon, business development manager at F2G said, "This alliance with Asinex represents an important relationship for F2G and offers a potentially broader collaboration in time.
"The quality of the Asinex compounds and their chemistry expertise will form the basis of an excellent long-term association.
"We believe there are specific areas of chemistry within the Asinex library that will be particularly valuable to F2G".
Dimitri Genis, CEO of Asinex, commented on the collaboration: "This alliance is a significant development for Asinex.
"We have progressed greatly in the last two years, and are now much more than just a supplier of compounds.
"We are becoming increasingly imaginative in our business strategy, and we hope that this will be the first of many such deals.
"F2G is an emerging leader in the area of anti-fungal drug discovery, and we are looking forward to working with them."
